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Abstract
Background: Inadequate vaccine stock management in health facilities leads to vaccine stock-outs. The latter
threatens the success of immunisation programmes. Countries have used various approaches to reduce stock-outs and
improve vaccine availability, but we are not aware of a systematic review of these interventions. This protocol describes
the methods we will use to assess the effects of existing approaches for improving vaccine stock management.
Methods: We include randomised and non-randomised studies identified through a compehensive search of
peer-reviewed and grey literature databases. We will search PubMed, Cochrane Central Register of Controlled
Trials, Embase, Web of Science, PDQ-Evidence and Scopus. We will also search websites of the World Health
Organisation (WHO), Global Alliance for Vaccine and Immunisation, PATH Vaccine Resources Library and United
Nations Children’s Fund. In addition, we will search the WHO International Clinical Trials Registry Platform and
reference lists of included studies and relevant reviews. Finally, we plan to do a citation search for included studies.
We will use Cochrane recommended methods to screen search outputs, assess study eligibility and risk of bias,
extract and analyse study results. We will use the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) tool to assess the certainty of the evidence on the effects of the interventions.
Discussion: We believe that the findings of this review will serve as valuable information for policy makers on
ways to improve vaccine stock management and vaccine availability. When vaccine availability is improved, those
who need them, especially children, will be adequately protected from vaccine-preventable diseases.
Systematic review registration: PROSPERO CRD42018092215
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Background
The success of immunisation programmes depends on
a well-functioning supply chain that ensures the con-
stant availability of quality vaccines to the target
population [1–3]. Effective vaccine stock management
is one of the criteria for an effective vaccine supply-
chain [1, 4]. Vaccine stock management at health
facility level involves the checking and monitoring of
vaccines on arrival at a storage point, during storage
and when they are administered to the users [1, 2].
Adequate vaccine stock management helps to main-
tain the quality of vaccines [1, 2] and prevent vaccine
stock-outs. Vaccine stock-outs refer to the absence of
vaccine(s) at the point of service delivery to the pa-
tient [3, 5]. An analysis of global data on effective
vaccine management assessments between 2009 and
2014 showed that most low- and middle-income
countries performed below the minimum standard for
adequate vaccine stock management [6].
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Recent data reported by countries in World Health Or-
ganisation (WHO) and United Nations Children’s Fund
(UNICEF) joint reporting show that each year at least
one-third of countries experience one or more vaccine
stock-outs lasting for at least 1 month [7]. The most vul-
nerable groups who suffer the effects of vaccine
stock-outs in resource-constrained settings are the urban
poor and rural communities who depend on public facil-
ities for health services. When vaccines are not available,
these recipients of public health services are obliged to
make repeated and costly trips to health facilities. Ultim-
ately, immunisation targets are not met, universal health
coverage remains an elusive dream and lives are lost [8].
Due to the upward trend in the rates of vaccine
stock-outs, countries are currently creating approaches to
improve vaccine stock management [7, 9]. The approaches
for improving vaccine availability may include the use of
digital systems to monitor vaccine stock levels in real time
[10–12] . These dashboards measure performance and make
them visible for managers to make informed decisions [13].
Another vaccine stock management approach involves the
crowd sourcing of reports of stock-outs from patients and
community volunteers. These reports are then sent to rele-
vant health system structures to elicit system changes for
improving vaccine availability [14]. However, we are not
aware of a systematic review of these and other potential in-
terventions for improving vaccine stock management.
Objective
We aim to assess the effects of approaches used for
vaccine stock management at facility level.
Methods
This systematic review protocol has been prepared ac-
cording to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses Protocol (PRISMA-P) 2015
guideline (Additional file 1).
Registration of the review
We registered the systematic review in the Inter-
national Prospective Register of Systematic Reviews
(PROSPERO) [15].
Eligibility criteria for studies
We will include individually randomised trials, cluster
randomised trials, controlled before-after studies,
interrupted time series studies and repeated
cross-sectional studies. Eligible participants include
the healthcare systems which deliver vaccines, health-
care facilities where vaccines are administered,
healthcare workers involved in providing immunisa-
tion services and recipients of immunisation services.
We plan to include interventions targeting recipients or
providers of immunisation services. Recipient-oriented
interventions may include the involvement of end-users
in monitoring vaccine availability at facilities, e.g. using
mobile phone services or hotline platforms. Examples
of interventions directed at providers of immunisation
services include education or training, audit and feed-
back, prompts or reminders and supportive supervi-
sion. We will also include interventions targeting the
health system offering immunisation services, e.g. ac-
tion plans, re-designing (components) of the supply
chain and integration with other services. Other inter-
ventions intended to ensure vaccine availability, includ-
ing multi-component interventions, are also eligible for
inclusion. We will consider the following as eligible
comparisons: standard vaccine stock management prac-
tices in the study setting, alternative interventions and
similar interventions implemented with different de-
grees of intensity.
Our primary outcomes are vaccine availability and
vaccine stock-outs. We will measure vaccine availabil-
ity as the proportion of vaccination days in which
vaccines were available and no one eligible for vaccin-
ation was turned back for lack of vaccines; but will
also consider other measures of vaccine availability
used by the authors of included studies. Vaccine
stock-out rates in the review will be measured as the
percentage of facilities that experienced a stock-out of
a specific vaccine that the site is expected to provide,
at any point, within a defined period; or other defini-
tions as used in included studies. Our secondary out-
comes include acceptability, adverse events and cost
of the intervention, as well as other outcomes as re-
ported by included studies.
Data sources
We will develop a comprehensive search strategy for both
peer-reviewed and grey literature. We will search the fol-
lowing databases PubMed, Cochrane Central Register of
Controlled Trials (CENTRAL), Embase, WHO Library In-
formation System (WHOLIS), Web of Science, PDQ
(Pretty Darn Quick)-Evidence and Scopus. We will also
search the websites of WHO, Global Alliance for Vaccine
and Immunisation, PATH Vaccine Resources Library and
UNICEF. In addition, we will search the WHO Inter-
national Clinical Trials Registry Platform, reference lists of
included studies and related systematic reviews and cita-
tions of included studies. A preliminary search strategy
developed for PubMed is found in the Appendix.
Data collection and analyses
Two authors will independently screen the titles and
summaries of records retrieved from the search for
potentially eligible studies. We will obtain full-texts
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for all the potentially eligible studies. Two authors
will assess these full-text publications for eligibility.
Any disagreements between the two authors regard-
ing study eligibility will be resolved by discussion and
consensus. A third author will arbitrate any unre-
solved disagreements. We will provide a table with
the characteristics of the included studies, and an-
other of excluded studies with reasons for their exclu-
sion. We will seek additional information, for studies
with missing information, to assist us in our
decision-making process.
For each included study, two authors will independ-
ently extract information using a piloted data extrac-
tion form. Extracted data will include study design,
participant, intervention and outcome characteristics
as well as outcome data. Any differences will be re-
solved through discussion and consensus. A third au-
thor will be consulted to arbitrate if disagreements
persist between the two authors. If there are missing
data, we will contact study investigators to obtain the
missing information. Two authors will independently
assess risk of bias in included studies using the appro-
priate tool for randomised trials [16] and non-rando-
mised studies [17]. Differences in judgement will be
resolved by discussion and consensus, with arbitra-
tion by a third author.
We will present study results as risk ratios for di-
chotomous data (e.g. frequency of vaccine stock-outs),
and mean differences for continuous data (e.g. dur-
ation of vaccine stock-outs) will be presented as mean
difference. We will combine data from clinically
homogenous studies (in terms of designs, participants,
interventions and outcomes) using random-effects
meta-analysis. However, if we come across variation
between studies, the findings will be summarised in a
narrative format. We will analyse results of inter-
rupted time series studies using regression analysis
with time trends before and after the interventions
[18, 19]. We will assess certainty of the evidence of ef-
fects of interventions using the Grading of Recom-
mendations, Assessment, Development and Evaluation
(GRADE) approach [16].
We will look out for and correct any errors made in
the analysis of included studies. For example, if clus-
tering is not addressed in an eligible cluster rando-
mised trial, we will re-analyse the data if sufficient
information is available. Otherwise, we will request
necessary data from the authors or attempt to adjust
data for clustering by inflating the standard errors by
multiplying them by the square root of the design ef-
fect [16]. The adjusted effect will then be added in the
meta-analysis. We will assess statistical heterogeneity
among study results using the I2 statistic. We will
consider heterogeneity as substantial, if the I2 is 50%
or more. We will investigate the causes of substantial
statistical heterogeneity using subgroup analyses. We
will define subgroups based on participant and study
design characteristics. We will use the chi-squared
test for subgroup differences to assess for subgroup
interactions. We will carry out sensitivity analyses, if
applicable on aspects that could potentially affect the
meta-analysis results such as study designs and over-
all risk of bias. We may also conduct a sensitivity ana-
lysis to explore the effects of fixed- versus random-
effects analyses for outcomes with statistical hetero-
geneity [16].
Discussion
This systematic review will examine the effectiveness
of existing approaches for managing vaccine stock
levels at health facilities, in order to prevent vaccine
stock-outs. Study findings will serve as valuable in-
formation for policy makers on ways to improve vac-
cine stock management and vaccine availability.
When vaccine availability is improved, target popula-
tions will be adequately protected from vaccine-pre-
ventable diseases. Furthermore, there will be
reduction in the number repeated visits that patients
should make in a bid to get vaccinated. This will in-
crease their trust in the health systems. Ultimately,
there will be a reduction in deaths caused by
vaccine-preventable diseases as well as an improve-
ment in other health outcomes.
Additional file
Additional file 1: PRISMA P checklist for the protocol. (DOCX 21 kb)
Appendix
Table 1 Search strategy for PubMed
Search Query Items found
7 Search (#1 OR #2 OR #12 OR 4 OR #5)
AND #6
83
6 Search (low-income countries) OR
(middle-income countries)
28798
5 Search (vaccines OR Vaccine) AND
“Supply and distribution”
2507
4 Search (Vaccine OR Vaccines) AND
“Supply chain Management”
15
3 Search “Vaccine stockout” OR
“Vaccines stockout”
3
2 Search drug storage AND
(Vaccine OR Vaccines)
994
1 Search “Vaccine stock management”
OR “Vaccine Management”
131
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